Humacyte (HUMA) Other Operating Expenses (2020 - 2026)
Humacyte (HUMA) posted quarterly Other Operating Expenses of $2.0 million for Q1 2026, up 1286.39% year-over-year from $147000.0 in Q1 2025, and down 77.56% quarter-over-quarter from $9.1 million in Q4 2025.
Humacyte (HUMA) Other Operating Expenses (2020 - 2026) Analysis & Trends
Humacyte (HUMA) has reported Other Operating Expenses for 3 consecutive years, with $2.0 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Other Operating Expenses rose 1286.39% year-over-year to $2.0 million; the TTM figure through Mar 2026 stood at $11.6 million (up 7786.39% YoY), while the FY2025 annual figure was $9.7 million, changed N/A from the prior year.
- Other Operating Expenses fell to $2.0 million in Q1 2026 per HUMA's latest filing, from $9.1 million in the prior quarter.
- Across five years, Other Operating Expenses topped out at $9.1 million in Q4 2025 and bottomed at $147000.0 in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Humacyte | 150.77 Mn | 150.77 Mn | -825,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.23 Mn |
| Mar 31, 2026 | 2.04 Mn |
| Dec 31, 2025 | 9.08 Mn |
| Sep 30, 2025 | 260,000.00 |
| Jun 30, 2025 | 213,000.00 |
| Mar 31, 2025 | 147,000.00 |
| Dec 31, 2020 | 16,191.00 |
| Sep 30, 2020 | -22,177.00 |